RNA binding to human METTL3-METTL14 restricts N6-deoxyadenosine methylation of DNA in vitro

  1. Shan Qi
  2. Javier Mota
  3. Siu-Hong Chan
  4. Johanna Villarreal
  5. Nan Dai
  6. Shailee Arya
  7. Robert A Hromas
  8. Manjeet K Rao
  9. Ivan R Corrêa Jr
  10. Yogesh K Gupta  Is a corresponding author
  1. The University of Texas Health Science Center at San Antonio, United States
  2. New England Biolabs, United States

Abstract

Methyltransferase like-3 (METTL3) and METTL14 complex transfers a methyl group from S-adenosyl-L-methionine to N6 amino group of adenosine bases in RNA (m6A) and DNA (m6dA). Emerging evidence highlights a role of METTL3-METTL14 in the chromatin context, especially in processes where DNA and RNA are held in close proximity. However, a mechanistic framework about specificity for substrate RNA/DNA and their interrelationship remain unclear. By systematically studying methylation activity and binding affinity to a number of DNA and RNA oligos with different propensities to form inter- or intra-molecular duplexes or single-stranded molecules in vitro, we uncover an inverse relationship for substrate binding and methylation and show that METTL3-METTL14 preferentially catalyzes the formation of m6dA in single-stranded DNA (ssDNA), despite weaker binding affinity to DNA. In contrast, it binds structured RNAs with high affinity, but methylates the target adenosine in RNA (m6A) much less efficiently than it does in ssDNA. We also show that METTL3-METTL14-mediated methylation of DNA is largely restricted by structured RNA elements prevalent in long noncoding and other cellular RNAs.

Data availability

The information about coding sequences of human METTL3 (NCBI reference sequence GI: 33301371) and METTL14 (NCBI reference sequence GI: 172045930) used in this study is available at NCBI. Source data are provided as a separate Source Data file. Correspondence and requests for material should be addressed to Y.K.G. (guptay@uthscsa.edu).

Article and author information

Author details

  1. Shan Qi

    Department of Biochemistry and Structural Biology, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0175-6267
  2. Javier Mota

    Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    No competing interests declared.
  3. Siu-Hong Chan

    RNA Biology, New England Biolabs, Ipswich, United States
    Competing interests
    Siu-Hong Chan, is an employee of New England Biolabs, a manufacturer and vendor of molecular biology reagents..
  4. Johanna Villarreal

    Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    No competing interests declared.
  5. Nan Dai

    RNA Biology, New England Biolabs, Ipswich, United States
    Competing interests
    Nan Dai, is an employee of New England Biolabs, a manufacturer and vendor of molecular biology reagents..
  6. Shailee Arya

    Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    No competing interests declared.
  7. Robert A Hromas

    Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    Robert A Hromas, owns equity in Dialectic Therapeutics and Abfero..
  8. Manjeet K Rao

    Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    No competing interests declared.
  9. Ivan R Corrêa Jr

    RNA Biology, New England Biolabs, Ipswich, United States
    Competing interests
    Ivan R Corrêa, is an employee of New England Biolabs, a manufacturer and vendor of molecular biology reagents..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3169-6878
  10. Yogesh K Gupta

    Department of Biochemistry and Structural Biology, The University of Texas Health Science Center at San Antonio, San Antonio, United States
    For correspondence
    guptay@uthscsa.edu
    Competing interests
    Yogesh K Gupta, is founder of Atomic Therapeutics. None of these affiliations affect the authors' impartiality, adherence to journal standards and policies, or availability of data..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6372-5007

Funding

Max and Minnie Tomerlin Voelcker Fund

  • Yogesh K Gupta

San Antonio Area Foundation

  • Yogesh K Gupta

IIMS/CTSA pilot award

  • Yogesh K Gupta

Greehey Children's Cancer Research Institute

  • Shan Qi
  • Yogesh K Gupta

University of Texas System

  • Yogesh K Gupta

National Institute of Allergy and Infectious Diseases (1R01AI161363)

  • Yogesh K Gupta

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Shozeb Haider, University College London, United Kingdom

Version history

  1. Received: February 2, 2021
  2. Preprint posted: January 9, 2022 (view preprint)
  3. Accepted: January 20, 2022
  4. Accepted Manuscript published: January 21, 2022 (version 1)
  5. Version of Record published: February 9, 2022 (version 2)
  6. Version of Record updated: April 4, 2022 (version 3)

Copyright

© 2022, Qi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,351
    views
  • 374
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shan Qi
  2. Javier Mota
  3. Siu-Hong Chan
  4. Johanna Villarreal
  5. Nan Dai
  6. Shailee Arya
  7. Robert A Hromas
  8. Manjeet K Rao
  9. Ivan R Corrêa Jr
  10. Yogesh K Gupta
(2022)
RNA binding to human METTL3-METTL14 restricts N6-deoxyadenosine methylation of DNA in vitro
eLife 11:e67150.
https://doi.org/10.7554/eLife.67150

Share this article

https://doi.org/10.7554/eLife.67150

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article

    Mediator of ERBB2-driven Cell Motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Isabelle Petit-Hartlein, Annelise Vermot ... Franck Fieschi
    Research Article

    NADPH oxidases (NOX) are transmembrane proteins, widely spread in eukaryotes and prokaryotes, that produce reactive oxygen species (ROS). Eukaryotes use the ROS products for innate immune defense and signaling in critical (patho)physiological processes. Despite the recent structures of human NOX isoforms, the activation of electron transfer remains incompletely understood. SpNOX, a homolog from Streptococcus pneumoniae, can serves as a robust model for exploring electron transfers in the NOX family thanks to its constitutive activity. Crystal structures of SpNOX full-length and dehydrogenase (DH) domain constructs are revealed here. The isolated DH domain acts as a flavin reductase, and both constructs use either NADPH or NADH as substrate. Our findings suggest that hydride transfer from NAD(P)H to FAD is the rate-limiting step in electron transfer. We identify significance of F397 in nicotinamide access to flavin isoalloxazine and confirm flavin binding contributions from both DH and Transmembrane (TM) domains. Comparison with related enzymes suggests that distal access to heme may influence the final electron acceptor, while the relative position of DH and TM does not necessarily correlate with activity, contrary to previous suggestions. It rather suggests requirement of an internal rearrangement, within the DH domain, to switch from a resting to an active state. Thus, SpNOX appears to be a good model of active NOX2, which allows us to propose an explanation for NOX2’s requirement for activation.